Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Gardner

Urology Indianapolis, IN Medical Doctor

NPI 1376538066 CMS profile 197736

535 Barnhill Dr, Rt 420, Indianapolis, IN 46202

Open in the dashboard

General payments

$3,810

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Gardner of Indianapolis, IN is reported in the CMS Open Payments database as having received $3,810 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $731 10
2024 General $365 4
2023 General $631 8
2022 General $300 7
2021 General $237 6
2020 General $14 1
2019 General $1,533 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gardner
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Thomas Gardner were reported at $731. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Thomas Gardner Urology median Middle half National median
2019 $1,533 $480 $147–$1,201 $163
2020 $14 $246 $87–$645 $114
2021 $237 $358 $111–$1,000 $132
2022 $300 $476 $143–$1,263 $149
2023 $631 $560 $168–$1,461 $160
2024 $365 $563 $170–$1,464 $164
2025 $731 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,180 22 payments
  2. NeoTract Inc. $985 3 payments
  3. Calyxo, Inc. $439 3 payments
  4. Astellas Pharma US Inc $224 3 payments
  5. Teleflex LLC $209 3 payments
  6. Kerecis Limited $176 1 payment
  7. Bluewind Medical $106 1 payment
  8. COMSORT, Inc $100 1 payment
  9. Merck Sharp & Dohme Corporation $96 1 payment
  10. Axonics Modulation Technologies, Inc. $76 1 payment
  11. Other $221 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,828 41 payments
  2. Travel and Lodging $708 1 payment
  3. Education $175 6 payments
  4. Consulting Fee $100 1 payment
Products named General payments · program years 2019–2025
  1. UROLIFT $1,175 5 payments
  2. AMS 700 $545 10 payments
  3. CVAC ASPIRATION SYSTEM $439 3 payments
  4. AMS $268 4 payments
  5. AMS 700 CXR RTE Kit $202 5 payments
  6. KEYTRUDA $196 2 payments
  7. Kerecis SurgiClose Wound Care $176 1 payment
  8. Kerecis SurgiClose Wound Care $176 1 payment
  9. Kerecis SurgiClose Wound Care $176 1 payment
  10. Kerecis GraftGuide $176 1 payment
  11. Other $879 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,061

Median for Urology: 1,053

Drug cost

$86,652

Median for Urology: $101,464

Branded share of claims

14.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 32 $39,260
Gemtesa Vibegron Brand 22 $11,600
Trimethoprim Generic 137 $8,005
Dutasteride Generic 226 $7,123
Tolterodine Tartrate Er Tolterodine Tartrate Brand 25 $4,859
Tamsulosin Hcl Generic 262 $4,141
Finasteride Generic 120 $2,442
Trospium Chloride Generic 18 $2,165
Solifenacin Succinate Generic 12 $1,896
Testosterone Generic 24 $1,855

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$135,495

Of which drugs: $9,542

Medicare patients

471

Average age 75

Services billed

1,903

69 women, 402 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 53%
Arthritis 42%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 29%
Depression 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record